Introduction to Europe Acute Care Syndromic Testing Market
The Europe acute care syndromic testing market was valued at $0.90 billion in 2022 and is expected to reach $2.32 billion by 2033, growing at a CAGR of 8.95% between 2023 and 2033. Molecular diagnostics techniques such as syndromic panels are capable of simultaneously detecting several pathogens. These pathogens typically exhibit comparable or overlapping clinical symptomatology, making patient management easier and specific symptom diagnosis more straightforward.

Market Introduction
The increasing demand for early infectious illness identification has led to a notable surge in the acute care syndromic testing industry in Europe. The incidence of pandemics and the prevalence of infectious diseases have been major contributors to this rise. Furthermore, the expansion of the industry has been aided by the rise in global temperatures and the discovery of new infectious diseases in different places.

Promising healthcare solutions are available in the European acute care syndromic testing sector, and more developments may be possible. The acute care syndromic testing market is growing as a result of the advancement of instruments for early detection, treatment planning, diagnosis, and monitoring of infectious diseases. The Europe market is witnessing increasing investments in healthcare infrastructure and the adoption of advanced diagnostic technologies, further boosting the growth of the acute care syndromic panel testing market. Additionally, favorable regulations and initiatives promoting the integration of syndromic panel testing in routine clinical.

Market Segmentation

Segmentation 1: by End User

  • Hospitals
  • Clinical and Diagnostic Laboratories
  • Research and Academic Institutions
  • Other End Users


Segmentation 2: by Country

  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe


How Can This Report Add Value to an Organization?
Product/Innovation Strategy: The Europe acute care syndromic testing market has been extensively segmented on the basis of various categories, such as end user and Country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: The Europe acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the Europe acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

  • Biocartis NV
  • bioM?rieux SA (BioFire Diagnostics)
  • DiaSorin S.p.A (Luminex Corporation)
  • Eurofins Scientific (Eurofins Viracor)
  • QIAGEN N.V.
  • QuantuMDx Group Ltd.
  • Siemens Healthineers AG


This report will be delivered in 3-5 working days.